We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The International Coalition of Medicines Regulatory Authorities (ICMRA) is about to start two pilot projects on drug manufacturing inspections, a senior industry official said. Read More
Teva Pharmaceuticals and Natco Pharma have announced the launch of the first generic versions of Revlimid (lenalidomide) in the U.S., a move that will take a bite out of Bristol Myers Squibb’s (BMS) profit from the blockbuster blood cancer drug. Read More
Various supply-chain resilience measures are needed to ensure U.S. drug production before the next pandemic or other natural disaster, a National Academy of Sciences, Engineering and Medicine (NASEM) expert panel advised in a new report. Read More
Nearly $80 million will be invested to bolster commercial-scale manufacturing for companies producing innovate technologies, such as cell and gene therapies. Read More
Almost a year after admitting it manipulated safety data for its anemia drug roxadustat, Fibrogen has disclosed that the Securities and Exchange Commission (SEC) is investigating its actions. Read More
Nevada’s action marks a growing trend among states to try to rein in the rising costs of prescription drugs — especially as the latest federal attempt at allowing Medicare to negotiate the price of some medications is stalled in the Senate. Read More
AstraZeneca’s and Sanofi’s investigational long-acting antibody aimed at infants with respiratory syncytial virus (RSV) had positive results in its phase 3 trial, making it the first potential immunization to show protection against RSV in the general infant population in a phase 3 trial, the companies said. Read More